DE69918523D1 - Neues glycosaminoglycan und dieses enthaltendes arzneimittel - Google Patents

Neues glycosaminoglycan und dieses enthaltendes arzneimittel

Info

Publication number
DE69918523D1
DE69918523D1 DE69918523T DE69918523T DE69918523D1 DE 69918523 D1 DE69918523 D1 DE 69918523D1 DE 69918523 T DE69918523 T DE 69918523T DE 69918523 T DE69918523 T DE 69918523T DE 69918523 D1 DE69918523 D1 DE 69918523D1
Authority
DE
Germany
Prior art keywords
glycosaminoglycan
disaccharide
uronic acid
residue
analyzed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69918523T
Other languages
English (en)
Other versions
DE69918523T2 (de
Inventor
Yutaka Kariya
Ryo Takano
Kaeko Kamei
Saburo Hara
Junichi Onaya
Yusuke Hori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Publication of DE69918523D1 publication Critical patent/DE69918523D1/de
Application granted granted Critical
Publication of DE69918523T2 publication Critical patent/DE69918523T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE69918523T 1998-07-31 1999-08-02 Neues glycosaminoglycan und dieses enthaltendes arzneimittel Expired - Lifetime DE69918523T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP21705198 1998-07-31
JP21705198 1998-07-31
JP24638798 1998-08-31
JP24638798 1998-08-31
PCT/JP1999/004155 WO2000006608A1 (fr) 1998-07-31 1999-08-02 Nouveau glycosaminoglycan et compositions medicamenteuses le contenant

Publications (2)

Publication Number Publication Date
DE69918523D1 true DE69918523D1 (de) 2004-08-12
DE69918523T2 DE69918523T2 (de) 2005-07-28

Family

ID=26521784

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918523T Expired - Lifetime DE69918523T2 (de) 1998-07-31 1999-08-02 Neues glycosaminoglycan und dieses enthaltendes arzneimittel

Country Status (10)

Country Link
US (1) US6492503B1 (de)
EP (1) EP1022289B1 (de)
JP (2) JP4575595B2 (de)
KR (1) KR20010030803A (de)
CN (1) CN1286699A (de)
AT (1) ATE270677T1 (de)
AU (1) AU4933099A (de)
CA (1) CA2305619C (de)
DE (1) DE69918523T2 (de)
WO (1) WO2000006608A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
EP2402753A1 (de) * 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analyse von sulfatierten Polysacchariden
DE10214507A1 (de) * 2002-04-02 2003-10-16 Beiersdorf Ag Verwendung von Acarbose und deren Derivaten zur Behandlung und Prophylaxe degenerativer Hautzustände
US7629967B2 (en) 2003-02-14 2009-12-08 Next Holdings Limited Touch screen signal processing
US8456447B2 (en) 2003-02-14 2013-06-04 Next Holdings Limited Touch screen signal processing
US8508508B2 (en) 2003-02-14 2013-08-13 Next Holdings Limited Touch screen signal processing with single-point calibration
EP1635782A1 (de) * 2003-05-24 2006-03-22 JUVENA (International) AG Gewebekulturmedien als bestandteil von kosmetika
EP1666503B1 (de) 2003-09-12 2010-05-05 Seikagaku Corporation Polysaccharid-pseudoschwamm
KR100577075B1 (ko) * 2004-06-16 2006-05-08 주식회사 티앤라이프시스템 칼슘염 및 인산염, 또는 인산칼슘염을 이용한 히아루론산정제방법
KR101288748B1 (ko) 2004-09-15 2013-07-23 세이가가쿠 고교 가부시키가이샤 광반응성 다당, 광가교 다당 생성물, 이들의 제조 방법 및이로부터 제조된 의료용 재료
US7659260B2 (en) * 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US8432377B2 (en) 2007-08-30 2013-04-30 Next Holdings Limited Optical touchscreen with improved illumination
BRPI0909849A2 (pt) 2008-04-04 2015-10-06 Univ Utah Res Found éteres semi-sintéticos de glicosaminoglicosanos e métodos para fazê-los e usá-los
ES2817779T3 (es) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP2688402B1 (de) 2011-03-23 2018-10-24 University of Utah Research Foundation Mittel zur behandlung bzw. prävention von harnwegsentzündungen
JP5263349B2 (ja) * 2011-08-08 2013-08-14 生化学工業株式会社 生理活性分子含有架橋ヘパリンゲル組成物
LT2794665T (lt) * 2011-12-19 2017-12-27 Dilafor Ab Neantikoaguliaciniai glikozaminoglikanai, apimantys pasikartojantį disacharido vienetą, ir jų medicininis panaudojimas
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
CA2912710C (en) * 2013-05-16 2020-06-30 Agency For Science, Technology And Research Heparan sulphates
CN103698425B (zh) * 2013-12-12 2015-08-26 中国海洋大学 一种化学降解法获得及检测生物来源糖胺聚糖二糖的方法
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
CN113388044B (zh) * 2020-03-11 2023-03-31 中国科学院昆明植物研究所 一种蜗牛糖胺聚糖化合物、其药学上可接受的盐、制备方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609043B2 (ja) * 1976-06-22 1985-03-07 生化学工業株式会社 脱硫酸化ムコ多糖体の製造法
CA2130295A1 (en) * 1993-08-26 1995-02-27 Richard A. Berg Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery
AU2435795A (en) 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
EP1371666B1 (de) * 1994-07-01 2007-08-15 Seikagaku Corporation Verwendung von desulfatiertem Heparin

Also Published As

Publication number Publication date
EP1022289B1 (de) 2004-07-07
ATE270677T1 (de) 2004-07-15
JP2010235956A (ja) 2010-10-21
KR20010030803A (ko) 2001-04-16
EP1022289A4 (de) 2001-10-17
CA2305619C (en) 2008-05-20
JP5189137B2 (ja) 2013-04-24
EP1022289A1 (de) 2000-07-26
CN1286699A (zh) 2001-03-07
JP4575595B2 (ja) 2010-11-04
CA2305619A1 (en) 2000-02-10
WO2000006608A1 (fr) 2000-02-10
DE69918523T2 (de) 2005-07-28
US6492503B1 (en) 2002-12-10
AU4933099A (en) 2000-02-21

Similar Documents

Publication Publication Date Title
DE69918523D1 (de) Neues glycosaminoglycan und dieses enthaltendes arzneimittel
AU3935695A (en) Keratan sulfate oligosaccharide fraction and pharmaceutical containing the same
EP0864582A3 (de) Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
Mourão et al. Structural features of sulfated glycans from the tunic of Styela plicata (Chordata‐Tunicata) A unique occurrence of L‐galactose in sulfated polysaccharides
ATE549402T1 (de) Alpha-isomaltosylglukosaccharidsynthase, verfahren zu deren herstellung und verwendung
MY124548A (en) Synthetic polysaccharides, preparation method therefor and pharmaceutical compositons containing same
ATE218587T1 (de) Polysaccharid, mikroorganismus und verfahren zu dessen herstellung, dieses enthaltende zusammensetzung und verwendung
Bayard et al. Hydrazinolysis and nitrous acid deamination of the carbohydrate moiety of α1-acid glycoprotein
Huang et al. Structure elucidation of glycan of glycoconjugate LbGp3 isolated from the fruit of Lycium barbarum L
ATE41785T1 (de) Membranoese polysaccharide, verwendbar insbesondere als arzneimittel und verfahren zu ihrer herstellung.
Gaidi et al. Two new biologically active triterpene saponins from Acanthophyllum squarrosum
Kenne et al. Structural studies of the Shigella flexneri variant X, type 5a and type 5b O‐antigens
Hopwood et al. Radiolabelled oligosaccharides as substrates for the estimation of sulfamidase and the detection of the Sanfilippo type A syndrome
BR9807759A (pt) Composto, e, processo para espessamento de um sistema aquoso
Shashkov et al. Cell wall anionic polymers of Streptomyces sp. MB-8, the causative agent of potato scab
Avigad et al. Fructosides formed from sucrose by a Corynebacterium
JPS5515445A (en) Introduction of amino-protecting group by microorganism
ES2233379T3 (es) Uso de esteres de azucares alcisilados en composiciones suavizantes liquidas acuosas.
Fransson et al. The copolymeric structure of pig skin dermatan sulphate. Characterization of d-glucuronic acid-containing oligosaccharides isolated after controlled degradation of oxydermatan sulphate
Ghosh et al. The extracellular polysaccharide produced by Rhizobium sp. isolated from the root nodules of Phaseolus mungo
Nelson et al. Partial characterization of lipid A of intraperiplasmically grown Bdellovibrio bacteriovorus
Urai et al. A novel viscous extracellular polysaccharide containing fatty acids from Rhodococcus rhodochrous ATCC 53968
JPS643116A (en) Plaster for patch
Zbiral et al. Elucidation of the topological parameters of N-acetylneuraminic acid and some analogues involved in their interaction with the N-acetylneuraminate lyase from Clostridium perfringens
Murata et al. High-performance liquid chromatographic identification of disaccharides generated from heparan sulphate isomers using heparitinases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition